Romiplostim N01 treatment group:None
Sponsors
Qilu Hospital of Shandong University, Henan Provincial People's Hospital
Conditions
Cancer therapy induced thrombocytopeniaPrimary immune thrombocytopenia
Phase 4
A Study on the Efficacy and Safety of Romiplostim N01 as Second-Line Therapy for Children with Primary Immune Thrombocytopenia
Active, not recruitingChiCTR2400091685
Start: 2024-11-01Updated: 2024-11-04
A Study on the Efficacy and Safety of Romiplostim N01 in Treating Patients with CTIT due to Malignant Hematological Diseases
Active, not recruitingChiCTR2400093333
Start: 2024-12-09Updated: 2024-12-09